Fairvalue-Calculator Fairvalue-Calculator
EN DE

PT Indofarma Tbk, (INAF) Fair Value & Analysis

Healthcare · ID · Market cap 391B IDR

Price126.00 IDR
Fair Value16.29 IDR
Upside-87.1%
Quality95/100
Evidence: Low Range 14.64 IDR – 18.89 IDR

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

PT Indofarma Tbk, (INAF) currently trades at 126.00 IDR, while our model-based Fair Value estimate is 16.29 IDR — implying the stock looks roughly 87.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

PT Indofarma Tbk, together with its subsidiaries, manufactures and sells pharmaceutical products in Indonesia and internationally. The company operates through medicine, Medical devices and Others, and Engineering Pharmaceuticals. It engages in marketing, trading and distribution of medicine and medical devices; and clinical lab. The company was formerly known as PT Indofarma (Persero) Tbk. PT Indofarma Tbk was founded in 1918 and is based in Bekasi, Indonesia. The company operates as a subsidiary of PT Bio Farma.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1949% Jiangsu Hengrui Pharmaceuticals Co (600276) -46% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -74% Hansoh Pharmaceutical Group (3692) -47% United Therapeutics Corporation (U2TH34) -73%

Frequently asked questions

Is PT Indofarma Tbk, (INAF) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 16.29 IDR versus a price of 126.00 IDR — about −87% (overvalued). Model-based estimate, not financial advice.
What is the fair value of INAF?
Our 21-model fair value for PT Indofarma Tbk, is 16.29 IDR (as of Jun 24, 2026), built from audited fundamentals. The current price is 126.00 IDR.
What is the quality score of INAF?
PT Indofarma Tbk, has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.